David Sinclair

David Sinclair runs a genetics lab at Harvard Medical School that he founded in 2004, the Paul F. Glenn Laboratories for the Biological Mechanisms of Aging [1]. He earned his PhD in molecular genetics at the University of New South Wales in 1995, working on gene regulation in yeast, before moving to MIT for postdoctoral work with Leonard Guarente on sirtuins [1].

In September 2019 Sinclair published Lifespan: Why We Age – and Why We Don't Have To, co-written with journalist Matthew LaPlante, which reached #11 on the New York Times bestseller list [2][6]. The book argues that aging is a single treatable process he calls information loss, and that sirtuin-activating compounds including resveratrol and NAD+ precursors such as NMN can slow it [2]. Sinclair has said publicly that he takes both resveratrol and NMN daily, a personal regimen he has repeated in interviews and on social media since around 2014, years before any completed randomized trial tested his combined stack in humans [2].

Sinclair's sirtuin work has drawn sustained technical criticism. His early claim that resveratrol activates SIRT1 directly, first published in a 2003 Nature paper, ran into a wall of failed replications; a 2005 paper by researchers including Aiken and Pfizer scientists reported that the fluorescence assay Sinclair's group used produced artifacts that made non-activating compounds look like activators, a finding GSK later addressed after acquiring Sirtris Pharmaceuticals, the company Sinclair co-founded, for roughly $720 million in 2008 [3][9]. GSK shut down Sirtris's lead resveratrol-derived compound program in 2010 after disappointing trial results and safety signals in multiple myeloma patients [9]. Charles Brenner, the biochemist who discovered nicotinamide riboside's vitamin activity, published a formal science-based review of Lifespan in Nutrients in 2022 stating that 25 years of academic and industrial work by multiple labs failed to confirm that sirtuins extend lifespan in yeast, worms, or vertebrates, and calling Sinclair's book a retelling of "the failure of the largest longevity medicine program in pharmaceutical history" [4][5].

Sinclair holds board or advisory roles across a wide set of companies with direct commercial exposure to the claims in his book. He co-founded MetroBiotech, whose NAD+-boosting compound MIB-725 entered human trials, and sits on its scientific advisory board [7]. He has separately consulted for or advised Elysium Health, a subscription NAD+ supplement company, and co-founded Life Biosciences (2017), Tally Health (2023, an at-home epigenetic-age testing company acquired by Infinite Epigenetics), Animal Biosciences, and several other longevity-adjacent startups, a list of more than a dozen active and past commercial affiliations that Sinclair discloses on his lab website [1][8].

His lab's December 2020 paper reported that three Yamanaka reprogramming factors delivered by virus safely reversed markers of age in mouse retinal neurons and partially restored vision in old mice and mice with a glaucoma-like injury, a finding built on by a 2023 conference poster claiming vision restoration in non-human primates, released alongside a company press release rather than as a peer-reviewed paper at the time [1]. Sinclair has said publicly that he believes there may be no fixed limit to human lifespan, framing aging as a loss of epigenetic information that could in principle be reset [1].

Critics outside Brenner have made a related point: sirtuin activation, NAD+ decline, and reprogramming are three distinct hypotheses, and Sinclair's public communication sometimes presents preliminary findings across all three as more settled than the primary literature supports. The 2022 Brenner review specifically flags that Lifespan omits a study showing partial reprogramming can cause tumors in mice, an omission relevant to readers evaluating the safety of the approach [4].

The plain takeaway: Sinclair has produced genuinely influential aging research, including foundational sirtuin biology and reprogramming experiments other labs have since built on, but he also personally profits from several companies selling products tied directly to his own public claims, and the specific quantitative promise that sirtuin activators or NMN extend human lifespan has not been confirmed in a completed randomized human trial as of 2026.